Cargando…

Long Term Progression-Free Survival in a Patient with Locally Advanced Prostate Cancer under Low Dose Intermittent Androgen Deprivation Therapy with Bicalutamide Only

Androgen deprivation is a common treatment option in patients with locally advanced or metastatic prostate cancer. No case of long term treatment with an intermittent approach with only low dose bicalutamide (50 mg daily) has been described yet. We report a 60-year-old patient, initially presenting...

Descripción completa

Detalles Bibliográficos
Autores principales:	Latz, Stefan, Fisang, Christian, Ebert, Wolfram, Orth, Stefan, Engehausen, Dirk G., Müller, Stefan C., Anding, Ralf
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2015
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4391157/ https://www.ncbi.nlm.nih.gov/pubmed/25883827 http://dx.doi.org/10.1155/2015/928787

Ejemplares similares

Minimally invasive treatment of female stress urinary incontinence with the adjustable single-incision sling system (AJUST ™) in an elderly and overweight population
por: Anding, Ralf, et al.
Publicado: (2017)

The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment
por: Ku, Ja Yoon, et al.
Publicado: (2015)

Efficacy of abiraterone acetate for high-risk hormone-naïve metastatic prostate cancer: A comparison with combined androgen blockade therapy with bicalutamide and androgen deprivation therapy alone
por: Kanao, Kent, et al.
Publicado: (2022)

Benefits of intermittent/continuous androgen deprivation in patients with advanced prostate cancer
por: MURESANU, HORIA
Publicado: (2016)

Intermittent androgen deprivation therapy in patients with prostate cancer: Connecting the dots
por: Abrahamsson, Per-Anders
Publicado: (2017)

Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer: A Randomized Clinical Trial
por: Vaishampayan, Ulka N., et al.
Publicado: (2021)

Prostate-specific antigen dynamics predict individual responses to intermittent androgen deprivation
por: Brady-Nicholls, Renee, et al.
Publicado: (2020)

Efficacy of Bicalutamide 150-mg Monotherapy Compared With Combined Androgen Blockade in Patients With Locally Advanced Prostate Cancer
por: Kang, Yu Jin, et al.
Publicado: (2014)

Chemical Degradation of Androgen Receptor (AR) Using Bicalutamide Analog–Thalidomide PROTACs
por: Kim, Ga Yeong, et al.
Publicado: (2021)

Efficacy of Immediate Switching from Bicalutamide to Flutamide as Second-Line Combined Androgen Blockade
por: Yokomizo, Yumiko, et al.
Publicado: (2016)

Measurement of bone turnover in prostate cancer patients receiving intermittent androgen suppression therapy
por: Theyer, Gerhard, et al.
Publicado: (2010)

Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system
por: Culig, Z, et al.
Publicado: (1999)

AB37. The combination of I brachytherapy with intermittent androgen deprivation in treating locally advanced prostate cancer
por: Huang, Yi
Publicado: (2014)

Intermittent androgen deprivation therapy: recommendations to improve the management of patients with prostate cancer following the GRADE approach
por: Bonfill, Xavier, et al.
Publicado: (2018)

Androgen deprivation and cognition in prostate cancer
por: Salminen, E, et al.
Publicado: (2003)

Charge density view on bicalutamide molecular interactions in the monoclinic polymorph and androgen receptor binding pocket
por: Korlyukov, Alexander A., et al.
Publicado: (2020)

Spectrophotometric Estimation of Bicalutamide in Tablets
por: Sancheti, P. P., et al.
Publicado: (2008)

Long-term treatment outcomes of intermittent androgen deprivation therapy for relapsed prostate cancer after radical prostatectomy
por: Maru, Shintaro, et al.
Publicado: (2018)

Synthesis and Biological Evaluation of Bicalutamide Analogues for the Potential Treatment of Prostate Cancer
por: Kandil, Sahar B., et al.
Publicado: (2020)

Synergic prodegradative activity of Bicalutamide and trehalose on the mutant androgen receptor responsible for spinal and bulbar muscular atrophy
por: Giorgetti, Elisa, et al.
Publicado: (2015)

Prostate cancer, insulin, and androgen deprivation therapy
por: Stattin, P, et al.
Publicado: (2003)

Three cases of nonmetastatic prostate cancer treated successfully with primary intermittent androgen deprivation therapy over 10 years
por: Shida, Yohei, et al.
Publicado: (2017)

Bicalutamide Activated Oncolytic Adenovirus for the Adjuvant Therapy of High Risk Prostate Cancer
por: Johnson, Tamara Jane, et al.
Publicado: (2013)

Identification of bicalutamide resistance-related genes and prognosis prediction in patients with prostate cancer
por: Li, Yuezheng, et al.
Publicado: (2023)

Compression-Induced Phase Transitions of Bicalutamide
por: Szafraniec-Szczęsny, Joanna, et al.
Publicado: (2020)

MicroRNA Library-Based Functional Screening Identified Androgen-Sensitive miR-216a as a Player in Bicalutamide Resistance in Prostate Cancer
por: Miyazaki, Toshiaki, et al.
Publicado: (2015)

Bicalutamide plus Aromatase Inhibitor in Patients with Estrogen Receptor‐Positive/Androgen Receptor‐Positive Advanced Breast Cancer
por: Lu, Qianyi, et al.
Publicado: (2019)

Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells
por: Chen, Mengqian, et al.
Publicado: (2010)

Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
por: Fujimoto, Naohiro, et al.
Publicado: (2011)

Cardiometabolic Complications after Androgen Deprivation Therapy in a Man with Prostate Cancer: Effects of 3 Years Intermittent Testosterone Supplementation
por: Aversa, Antonio, et al.
Publicado: (2012)

Intermittent versus continuous androgen deprivation for locally advanced, recurrent or metastatic prostate cancer: a systematic review and meta-analysis
por: Botrel, Tobias Engel Ayer, et al.
Publicado: (2014)

Intermittent chemotherapy in metastatic androgen-independent prostate cancer
por: Beer, T M, et al.
Publicado: (2003)

Reply: Prostate cancer, insulin and androgen deprivation therapy
por: Lehrer, S
Publicado: (2003)

Androgen deprivation therapy for prostate cancer and risk of dementia
por: Robinson, David, et al.
Publicado: (2019)

Androgen deprivation therapy in high risk prostate cancer
por: Van Dams, Ritchell, et al.
Publicado: (2019)

Cardiovascular Risks of Androgen Deprivation Therapy for Prostate Cancer
por: Corona, Giovanni, et al.
Publicado: (2021)

Improving intermittent androgen deprivation therapy: lessons learned from basic and translational research
por: Parikh, Rahul A, et al.
Publicado: (2014)

Intermittent Androgen Suppression: Estimating Parameters for Individual Patients Based on Initial PSA Data in Response to Androgen Deprivation Therapy
por: Hirata, Yoshito, et al.
Publicado: (2015)

Impact of Androgen Deprivation on Oxidative Stress and Antioxidant Status in Nigerian Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy
por: Bassey, Iya Eze, et al.
Publicado: (2020)

Can local treatment prolong the sensitivity of metastatic prostate cancer to androgen deprivation or even prevent castration resistance?
por: Niklas, Christina, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rr0vfnq7sahcb3bnik6njug22e